ERAS Stock Surges 65% With A 7-day Spree On Wainwright’s $11 Target
Erasca (ERAS) – a developer of oral ERK1/2 inhibitors for RAS/MAPK cancers – hit 7-day winning streak, with cumulative gains over this period amounting to a 65%. The company market cap has surged by about $1.2 Bil over the last 7 days, and currently stands at $2.9 Bil.
The stock has YTD (year-to-date) return of 176.6% compared to 1% for S&P 500. Let’s take a look at what’s driving the stock.
What Triggered The Rally?
[1] Positive Early Clinical Data for ERAS-0015
- Confirmed partial responses in RAS-mutant tumors
- Favorable safety and tolerability profile
- Impact: Stock price surge of 41.5% in a week, Increased investor enthusiasm
[2] H.C. Wainwright Price Target Increase
- Price target raised to $11 from $6
- Maintained “Buy” rating
- Impact: Strengthened Investor Confidence, Significant Price Momentum
Why This Matters?
Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.
But here is the real interesting point.
You are reading about this 65% move after it happened. The market has already priced in the news. To catch the next winner before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has flagged 5 new opportunities that haven not surged yet.
Returns vs S&P 500
The following table summarizes the return for ERAS stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | ERAS | S&P 500 |
|---|---|---|
| 1D | 2.4% | 0.5% |
| 7D (Current Streak) | 65.2% | -0.9% |
| 1M (21D) | 198.3% | 1.2% |
| 3M (63D) | 332.4% | 2.6% |
| YTD 2026 | 176.6% | 1.0% |
| 2025 | 48.2% | 16.4% |
| 2024 | 17.8% | 23.3% |
| 2023 | -50.6% | 24.2% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 43 S&P constituents with 3 days or more of consecutive gains and 29 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 29 | 16 |
| 4D | 7 | 5 |
| 5D | 2 | 6 |
| 6D | 2 | 2 |
| 7D or more | 3 | 0 |
| Total >=3 D | 43 | 29 |
Key Financials for Erasca (ERAS)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-141.5 Mil | $-157.1 Mil |
| Net Income | $-125.0 Mil | $-161.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-30.6 Mil | $-32.5 Mil |
| Net Income | $-33.9 Mil | $-30.6 Mil |
While ERAS stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.